Insmed Third-Quarter 2026 Financial Results - INSMED INC

Explicit Guidance:

• FY2026 Brinsupri Revenue: Raised to $1.35–$1.40 billion (increase of $100 million to low end; $50 million increase to midpoint of prior range).
• FY2026 EraCase Revenue: Raised to $460–$470 million (increase of $10 million to low end of prior range).
• 2026 Gross-to-Net Ratios: Brinsupri guidance reiterated at mid-to-high 20s; EraCase guidance reiterated at low-to-mid 20s.
• IRA Small Manufacturer Provision Impact: EraCase gross-to-net costs projected to increase to 5% in 2027, then continue annually increasing until reaching a 20% maximum cap in 2031.
• Cash Flow: Company expects to achieve cash flow positivity in 2027 despite continued investment in the pipeline.

Business-Segment Outlook:

• Brinsupri (Bronchiectasis):
  • Peak Sales: Current estimate >$7 billion, with significant potential upside from treating COPD and asthma comorbid patient populations (estimated low single-digit millions).
  • Treatment Penetration: Growth expected as physicians shift focus from severe/high-exacerbation patients to earlier-line use in moderate populations; projected to become a "statin for the lungs."
  • Commercial Initiatives: Launch of first branded TV campaign next month (projected ROI of 2–3x or higher) to drive new patient starts and awareness.
  • Comorbid Strategy: Initiatives to identify undiagnosed bronchiectasis in COPD/asthma patients (targeting ~32 million US patients) expected to expand addressable population to several million; initial findings on prevalence expected mid-2027.
  • International: Japan launch successful with $25mg tablets; Japanese patients showed 68% reduction in exacerbations (vs. 20% global) and >2x lung function improvement. Japan expected to be the primary driver for ex-US sales.
• EraCase (MAC Lung Disease):
  • Label Expansion: FDA Priority Review granted for MAC lung disease indication; PDUFA date set for January 28, 2027.
  • Launch Timeline: Expanded label launch in US and Japan targeted for first half of 2027 (assuming US and PMDA submissions in Q4 2026 are successful).
  • Market Size: Addressable market projected to expand from ~15,000 to >100,000 patients in the US and >100,000 in Japan (total TAM >200,000).
  • Peak Sales Potential: Potential to exceed $1 billion in peak sales post-expansion.
• TPIP (Inhaled Prostanoid):
  • Peak Sales: Projected to hit the market by end of decade (2029) with peak sales of >$6 billion across four indications (PHILD, PAH, PPF, IPF).
  • Clinical Enrollment: PALM ILD study >35% enrolled; full enrollment expected H1 2028. PALM PAH study enrolled first patient; PALM PPF study initiated; PALM IPF study to initiate H1 2027.
• New Pipeline Programs:
  • INS1033 (DPP-1): Phase 1 data expected 2027; if positive, Phase 2 in Rheumatoid Arthritis, Ulcerative Colitis, and COPD initiated in 2027.
  • INS1148: Phase 2 study in IPF planned for 2027, with plans to evaluate in PPF and other fibrotic diseases.
  • Gene Therapy (INS1201): Phase 1 in DMD fully enrolled; initial data to be shared in 2027. Phase 1 in ALS (INS1202) in Cohort 2; initial data to be shared in 2027.

Market and Competitive Outlook:

• Competition: Anticipated approval of other DPP-1 inhibitors; company expects to differentiate via superior efficacy (68% exacerbation reduction in Japanese cohort) and convenience (once-daily dosing, better safety).
• Diagnostic Landscape: Active efforts to change clinical practice via AI-powered diagnostic tools and "Suspect BE" awareness campaigns; aim to make high-res CT scan evaluation for bronchiectasis a default protocol.
• Real-World Evidence (RWE): BEST-BE study (1,000 US patients) and MBARC collaboration (3,000 European patients) underway to demonstrate long-term disease modification and safety.
• Prescriber Strategy: Focus on "depth" with top-tier pulmonology centers and community practices; breadth expansion expected as physician awareness of patient benefits increases.

Macro / Industry Outlook:

• Regulatory: FDA confirmed no advisory committee meeting planned for EraCase MAC indication.
• Payer Environment: High approval rates and reauthorization rates reported; medical exception processes remain effective for patients with non-contracting payers. No immediate anticipated friction regarding reimbursement for expanded patient populations.
• Seasonality: Management does not anticipate significant seasonality impacts on Q4 or early 2027, noting patient persistence is the primary growth driver.

Strategic Initiatives:

• AI Deployment: Developing and integrating AI-powered tools with software manufacturers and hospitals to flag bronchiectasis in medical records alongside lung cancer, COPD, and asthma.
• Disease Education: Deploying a team of 16 trained nurses as disease educators to engage pulmonologists in high-concentration sites.
• R&D Pipeline: Reiterated guidance to submit 1–2 INDs per year through the end of the decade; nine research programs currently in line for clinic entry between now and 2029.
• Business Development: Active search for external assets ("like Brinsupri") to complement the internal pipeline.
• Leadership Transition: CEO Will Lewis to remain; outgoing CFO Sarah Bonstein departs after overseeing financial architecture and capital formation.

Risks and Headwinds to Outlook:

• Competitive Entry: Potential market disruption from competitors' DPP-1 approvals; risk that clinical data from these competitors could alter physician perception.
• Real-World Performance: Risk that RWE studies (BEST-BE, MBARC) may show different efficacy profiles compared to Phase III trials, particularly if patient mixes differ.
• Regulatory Uncertainty: Potential delays in US or Japan label expansion approvals could impact 2027 launch timing and revenue trajectory.
• Enrollment Variance: Clinical trial enrollment timelines (particularly for PAH) could be impacted by physician response to emerging data or competitive trial landscapes.
• Comorbidity Detection: The "oil tanker" nature of changing diagnostic protocols means the full impact of the COPD/asthma comorbidity opportunity may not be realized until 2028 and beyond.
• IRA Cost Increases: Rising manufacturer coverage costs for EraCase starting in 2027 (5% to 20% cap by 2031) will expand gross-to-net deductions.

Management Tone on the Future:

• Confidence: High confidence in Brinsupri's "blockbuster" status and ability to generate 20%+ CAGR over the next 10 years; management describes the company as "set apart from peers."
• Optimism: Strong optimism regarding TPIP's differentiation and potential to "supercharge growth"; belief that EraCase will reach the forefront of MAC lung disease treatment.
• Strategic Patience: Willingness to invest heavily in long-term evidence generation (AI, RWE) despite lagging indicator timelines; emphasis on "operational excellence" scaling commercial and clinical capabilities.
• Hedges: Acknowledges that actual results may differ due to risks and uncertainties; cautions against modeling heavy seasonality until spring 2027 data is available.

Miscellaneous:

• Market Size Updates: Reiterated that undiagnosed bronchiectasis in COPD/asthma patients could represent 4–64% of the COPD population (conservative estimate >800,000 patients, likely higher).
• Enrollment Data: PALM ILD enrollment is ~6 months ahead of schedule; Phase 1 gene therapy data to be shared in 2027.
• Financial Metrics: Q3 2026 positive product revenues $78.2M (14.9% of total); Cash and equivalents $1.1B as of Q3 end.